Gyre Therapeutics, Inc. (GYRE) posted a net loss of $85.5 million for the full year ended December 31, 2023, compared to net income of $4.3 million, last year. Net loss per share was $1.41 compared to profit of $0.03.
For the full year ended December 31, 2023, revenues were $113.5 million as a result of Gyre's indirect controlling interest in Gyre Pharmaceuticals. Revenues were $102.3 million, for the prior year.
As of December 31, 2023, Gyre had cash and cash equivalents of $33.5 million, compared to $25.2 million as of December 31, 2022.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.